ImmunoGen Logo
US45253H1014
878613
IMGN

ImmunoGen

Forecast

The analysts' average price target is €13.48 (-53.77%). The median is €14.58 (-50.00%).

Buy
  6
Hold
  15
Sell
  1

Discussions in the community

There is no discussion about this asset yet.

Start discussion

There is currently no news available for this company. We are working on adding more providers to change this.

Financials

In the last year, ImmunoGen had revenue of €101.41M and net profit of -€207.83M

(EUR) 2022
YoY
Revenue 101.41M 65.08%
Gross profit 101.25M 64.82%
Net profit -207.83M 69.65%
EBITDA -201.15M 71.82%

Fundamentals

Metric Value
Market capitalization
€7.95B
Number of shares
279.35M
52-week high/low
€28.48 - €3.29
Dividends No
Beta
1.17
P/E ratio
-35.54
PEG ratio
-0.52
P/B ratio
50.84
P/S ratio
80.21

Company profile

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Name
ImmunoGen
CEO
Mark Joseph Enyedy
Headquarters Waltham, ma
USA
Website
Sector
Health Care
Industry
Biotechnology
IPO
11/17/1989
Employees 277

Ticker symbols

Exchange Symbol
NASDAQ
IMGN
🍪

Parqet  uses cookies. Learn more